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What’s new? 17 
 This study is the first to explore the gut microbiota in people with type 1 diabetes 18 
(T1D), but otherwise have good glycaemic control and high physical-fitness 19 
 The gut microbiota from the people with T1D and good glycaemic control and high 20 
physical-fitness was comparable to matched non-diabetic healthy controls 21 
  22 
2 
Abstract  23 
Aim: Type 1 diabetes (T1D) is the product of a complex interplay between genetic 24 
susceptibility and exposure to environmental factors. Existing bacterial profiling studies 25 
focus on people who are most at risk at the time of diagnosis; there is limited data on the gut 26 
microbiota of people with long standing T1D. This study compared gut microbiota of people 27 
with T1D and good glycaemic control and high levels of physical-fitness with matched non-28 
diabetic controls. 29 
Methods: Ten males with T1D and ten matched controls without diabetes (CON) were 30 
recruited; groups were matched for gender, age, BMI, VO2max, exercise habits. Stool samples 31 
were analysed using next generation sequencing of the 16S rRNA gene to obtain bacterial 32 
profiles from each individual. Phylogenetic investigation of communities by reconstruction of 33 
unobserved states (PICRUSt) was implemented to predict functional content of the bacterial 34 
OTUs.  35 
Results: Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were typically the most 36 
abundant members of the community in both T1D and CON and were present in every 37 
sample in the cohort. Each bacterial profile was relatively individual and no significant 38 
difference was reported between the bacterial profiles or the Shannon diversity indices of 39 
T1D compared with CON. The functional profiles were more conserved and the T1D group 40 
were comparable to that of the CON group. 41 
Conclusions: We show that both gut microbiota and resulting functional bacterial profiles 42 
from people with longstanding T1D in good glycaemic control and high physical-fitness 43 
levels are comparable to matched people without diabetes.  44 
3 
Introduction 45 
Type 1 diabetes (T1D) is the product of a complex interplay between genetic susceptibility 46 
and exposure to environmental factors [1]. Environmental exposure has long been implicated 47 
in the pathogenesis of the disease and now, with decades of evidence mapping an increased 48 
rate of incidence, it is clear that disease progression occurs at a rate at which genetic change 49 
alone cannot be solely accountable [2]. 50 
Previous research has shown that the gut microbiota, which is the collection of 51 
microorganisms colonizing the gut, has important roles in the disease [3–5]. Germ-free (GF) 52 
mice models of T1D may acquire the disease at higher rates, but this has been challenged 53 
with no significant differences between GF and colonized mice [6]. In the same study a 54 
Gram-positive organism was isolated which reduced the incidence of the disease. 55 
Administering ‘probiotic’ (live microorganisms which confer health benefits) to mouse 56 
models further demonstrated the potential of intervention targeting the gut microbiota to 57 
reduce disease incidence [6]. Antibiotic administration earlier in life may also predispose 58 
patients to T1D through modulation of the gut microbiota, where certain antibiotic 59 
combinations were recently found to increase diabetes risk [7], although in mice the 60 
incidence was reduced with vancomycin from birth to weaning [8]. 61 
Research in children has shown that the gut microbiota in Finish people with T1D had greater 62 
Bacterodetes relative to Firmicutes and reduced overall diversity [9]. More recently in a 63 
Spanish cohort, people with T1D had increased abundance of Clostridium, Bacteroides and 64 
Veillonella and reduced abundance of Bifidobacterium and Lactobacillus compared to 65 
controls [10]. Interestingly the latter two organisms are regarded as beneficial and have been 66 
used extensively as probiotic candidates.  Overall these findings indicate that interactions 67 
between the intestinal microbiota and the innate immune system are critical for disease 68 
development [9,11]. However, T1D has a wide spectrum of severity and these studies tend to 69 
4 
focus on people at who are most at risk at the time of diagnosis. Thus an important 70 
knowledge gap remains in the literature regarding the status of people in adulthood with 71 
longstanding diabetes. Moreover, there is limited data examining such individuals who are 72 
intensively managed, demonstrating good glycaemic control and high levels of physical 73 
fitness.  74 
This study seeks to explore gut microbiota in people with T1D and good glycaemic control 75 
and high levels of physical-fitness, matched to people without diabetes. While the gut 76 
microbiota potentially contributes to the T1D onset, we aimed to determine if long-term 77 
active suffers are able to develop a gut microbiome comparable to healthy controls or if 78 
important differences persist long after onset.  79 
5 
Materials and Methods 80 
Participant recruitment and preliminary testing 81 
Fully informed written consent was obtained from all persons following the study’s approval 82 
from National Health Service NRES Committee - Tyne and Wear South. Participants 83 
attended the Newcastle National Institute for Health Research Clinical Research Facility to 84 
establish peak cardio-respiratory parameters during the completion of an incremental-85 
maximal treadmill running protocol as previously described [12]. Participants provided stool 86 
material on tissue paper that was deposited in a sterile falcon tube and stored at -80 ºC until 87 
processing. Tissue paper was sterilised under UV and a negative control sample of toilet 88 
paper was also carried out. 89 
T1D eligibility criteria consisted of being aged between 18-35 years, a duration of diabetes > 90 
5 years, and an HbA1c < 8.0% (64 mmol/mol). In addition, people with T1D were required to 91 
be absent of diabetes-related complications, other than mild-background retinopathy, not 92 
receiving any medication other than insulin (assessed against recent medical notes), and 93 
regularly and consistently undertaking exercise (participating in aerobic based exercise for a 94 
minimum of 30 minutes at a time, at least three times per week). Ten male people with T1D 95 
were recruited (aged 27±2 years, BMI 23.5±0.7 kg.m2, VO2peak 51.3±2.2 ml/kg/min, 96 
duration of diabetes 12±2 years, HbA1c 7.1±0.4% [54.5±2.1 mmol/mol]). Patients were 97 
treated with a basal-bolus regimen composed of long-acting insulins glargine (n = 8) or 98 
detemir (n = 2), and rapid-acting insulin aspart. Eligibility criteria for non-diabetic control 99 
participants consisted of being between 18-35 years, regularly and consistently undertaking 100 
exercise. Ten male people without diabetes (CON) were recruited (aged 27±2 years, BMI 101 
22.4±0.8 kg/m2, VO2max 50.9±1.2 ml/kg/min). T1D and CON groups were matched for age, 102 
fitness and BMI (P>0.05). Both groups were habitually consuming a predominantly 103 
6 
carbohydrate rich diet (>60% carbohydrate) assessed via 24 hour recall. Study demographics 104 
are summarised in Table 1. 105 
 106 
16S rRNA gene bacterial profiling 107 
Participants were provided 3 sections of toilet paper from the same roll that had all undergone 108 
UV sterilisation. Following excrement the participants used the toilet paper once, the soiled 109 
tissue was then collected in sterile universal tubes. Nucleic acid extraction of stool was 110 
carried out on a section of the soiled toilet paper using the PowerLyzer™ PowerSoil® DNA 111 
Isolation Kit (MoBio, CA, USA) in accordance with the manufacturer’s instructions. 112 
Bacterial profiling utilised the 16S rRNA gene targeting variable region 4 and was carried out 113 
by NU-OMICS (Northumbria University) based on the Schloss wet-lab MiSeq SOP and 114 
resulting. raw fastq data were processed using Mothur (version 1.31.2) as described 115 
previously [13]. Briefly, combined reads were trimmed to 275 reads with 0 ambiguous bases. 116 
Chimeric sequences were detected by Chimera.uchime and removed from downstream 117 
analysis. Alignment was generated via the Silva v4 database [14] and Chloroplast, 118 
Mitochondria, unknown, Archaea, and Eukaryota linages were removed from the analysis. In 119 
total, 5,165,964 reads were generated from the 20 samples. Sequences were deposited in MG-120 
RAST under the accession numbers 4603090.3 - 4603109.3. 121 
 122 
Statistical analysis 123 
Data was normalised by subsampling and rarefying all samples to 104,142 reads. The data 124 
was automatically transformed and analysed by principal coordinate analysis (PCA) using 125 
SIMCA 13.0 (Umetrics, Stockholm, Sweden) [15]. The community structure between the 126 
T1D and CON groups were analysed by Parsimony and weighted UniFrac analysis [16]. 127 
Significant operational taxonomic unit (OTUs) were classified by the metastats function in 128 
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Mothur using 1000 permutations with multiple hypothesis testing correction [17]. 129 
Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) 130 
was implemented to predict functional content of the bacterial OTUs [18].   131 
8 
Results 132 
The number of reads used in the subsampling (104,142) facilitated robust coverage of the gut 133 
microbiota of each individual in the cohort. No significant difference was found between the 134 
T1D and control groups using Parsimony (P = 0.309) and weighted UniFrac (P = 0.107) 135 
Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were typically the most abundant 136 
members of the community in both T1D and CON and were present in every sample in the 137 
cohort (Figure 1). Levels of Bacteroides sp. tended to be higher in CON (P = 0.06) and 138 
Bifidobacterium sp. tended to be higher in T1D (P = 0.08), but neither was significant.  139 
The bacterial profiles of T1D were comparable to the CON group with no distinct clusters 140 
based on the bacterial profiles (Figure 2A). To account for potential false negatives resulting 141 
from some people with T1D, where HbA1c was outside the range for truly excellent control, 142 
further ordination analysis was conducted by stratifying T1D by HbA1c by > or < 53 143 
mmol/mol. PCA analysis with this classification showed no distinct clustering based on the 144 
overall bacterial community, with resulting PLS-DA predictive (Q) scores of -0.106 in >53 145 
mmol/mol and 0.022 in <53, where scores of >0.5 represent significant differences and 146 
predictively between the groups (Supplementary Figure 1). Only 17 OTUs from a total of 147 
3,062 were found to be significantly different between the groups (Table 2). Actinomyces sp. 148 
(OTU00428) was the most significant OTU (P = 0.008) in the T1D group and this was most 149 
associated with the T1D group in the PLS-DA loadings plot (Figure 2B). However, this OTU 150 
was detected in all but 2 participants (both from CON) and only compromised of 62 reads 151 
from a total of 2,082,840 (0.003%), where 49 reads were from people with T1D and 13 reads 152 
were from CON. No significant difference (P = 0.344) was found in the Shannon Diversity 153 
(H') between each group. The average T1D H' was 3.37 (range 2.16 – 3.92), whereas the 154 
CON H' was 3.13 (range 2.62 – 4.49). 155 
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PICRUSt was implemented to predict functional content of the bacterial OTUs. This showed 156 
that despite the relatively large variation in of the bacterial community between individuals, 157 
the functional profiles were much more comparable (Figure 3). Functional profiles from the 158 
T1D group were comparable to that of the CON group. 159 
10 
Discussion 160 
Alterations in the gut microbiota, whether causative or as a result of T1D, may have 161 
important implications for the health of people with T1D. The aim of the present study was to 162 
explore gut microbiota in people with T1D but good glycaemic control and high levels of 163 
physical-fitness, matched to people without diabetes. We show for the first time that 164 
intensively managed T1D suffers with optimal glycaemic control and good physical-fitness 165 
display comparable gut microbiota profiles to matched non-T1D individuals. 166 
The gut microbiota profiles were highly individual across the whole cohort, but there is 167 
general conformity between the most dominant members of the community. 168 
Faecalibacterium sp., Roseburia sp., and Bacteroides sp. were found to be the most abundant 169 
in the cohort and generally represented a substantial proportion of the gut microbiota in each 170 
person. These have been previously shown to be prevalent in a healthy adult gut microbiota 171 
[19]. The most significant OTUs driving the separation of the T1D and control gut 172 
communities were generally low in abundance and reflected only a small proportion of the 173 
overall reads. For example the Actinomyces sp. (OTU00428), which was the most significant 174 
OTU in the T1D group, only compromised of 62 reads (49 reads from T1D group) from a 175 
total of 2,082,840 (0.003%). Thus OTUs with such universally low relative abundance are 176 
unlikely to be contributing to disease pathophysiology and implying causality to disease 177 
should be avoided. While the cohort employed in this study is small, 10 T1D suffers are 178 
comparable to that of previously published studies and should not influence the lack of 179 
clinically important OTUs discriminating people with T1D and controls [10]. Previous 180 
studies have also inferred associations at diagnosis of increasing Bacteroides and reduced 181 
Bifidobacterium in T1D [9,10]. While these organisms were relatively abundant overall we 182 
see opposing trends, with lower Bacteroides and increased Bifidobacterium in T1D; although 183 
11 
these differences are noteworthy they were not significant, but further work in a larger cohort 184 
is necessary to confirm these observations. 185 
The Shannon diversity was comparable between T1D and controls with no significant 186 
difference found between the groups. Interestingly, previous studies suggest that children 187 
with T1D undergo dysbiosis of the gut microbiota, resulting in reduced diversity compared to 188 
people without diabetes [9,20]. The diversity reported in this study is comparable to that of a 189 
non-T1D adult population, but a lack of published aged-matched controls prevents any 190 
comparison with T1D adults. Nonetheless, the observation that active adults with T1D have a 191 
similar diversity to adults without T1D is important. 192 
Previous studies have suggested an increase of butyrate-producing and mucin-degrading 193 
bacteria in controls, whereas bacteria that produce short chain fatty acids (SCFAs) other than 194 
butyrate were higher in disease cases [21]. Thus synthetic pathways may represent a key 195 
etiological trigger in the onset of T1D. Functional analysis of the bacterial community in this 196 
dataset demonstrated comparability between the bacterial pathways of the OTUs found in 197 
people with T1D and matched controls. Despite large variation at the OTU level, the function 198 
profiles showed much greater comparability, as has been previously reported [22]. 199 
Noteworthy is that these functional pathways represent only those of the bacterial community 200 
based on the classification OTUs and thus do not account for differential gene expression 201 
between the two groups. 202 
Given the individual nature of the gut microbiota within each group of the cohort, it is 203 
perhaps not surprising that the ordination analysis of the bacterial profiles showed no distinct 204 
separation of people with T1D and matched controls. Thus, in adulthood the gut microbiota is 205 
not significantly altered in active persons as a result of being diagnosed with T1D. Notably 206 
this finding was not influenced when the T1D group was further stratified to account for 207 
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ranging HbA1c. Existing comparable data is limited, with studies to date focusing on 208 
differences in the gut microbiota in patients at the time of diagnosis (i.e. childhood) [9,10]. 209 
While the gut microbiota may serve as an environmental trigger in the onset of T1D in 210 
patients where genetic elements alone cannot account for the pathogenesis, an important 211 
finding of this study is that active T1D adults have a gut microbiota reflective of non-T1D 212 
adults. Further work should sample greater numbers of people temporally and seek to include 213 
sedentary sufferers and those with poorer glycaemic control. Future work should also 214 
consider T1D patients with other pathologies, such as retinopathy or cardiovascular disease. 215 
Considering the lack of available data pertaining to the influence of exercise on gut 216 
microbiota, profiling patients across a range of glycaemic control and physical-activity levels 217 
is warranted to ascertain whether alterations in gut microbiota are influenced by exercise, 218 
glycaemic control, or both, and if intervention or therapeutic manipulation of the gut 219 
microbiota could confer improvements to well-being. The potential influence of differences 220 
in HLA genotype between those with and without T1D should also be considered in future 221 
studies. 222 
In summary, this study confirmed existing data relating to the dominant bacterial organisms 223 
in the healthy active adult gut microbiota. Importantly, we show that both gut microbiota and 224 
resulting functional bacterial profiles from people with longstanding T1D in good glycaemic 225 
control and high physical-fitness levels are comparable to matched people without diabetes.  226 
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Table 1 – Individual participant characteristics 
Group 
Subject 
ID 
Age 
(years) BMI 
VO2peak 
(ml/kg/min) 
Fasting Blood 
Glucose 
(mMol/L) 
Diabetes 
Duration 
(years) 
HbA1c 
(mmol/mol) 
Control 
C1 25 22.1 50 4.20 
  
C2 23 21.4 51 4.32 
  
C3 31 21.7 56 4.33 
  
C4 30 20.1 52 3.87 
  
C5 28 26.9 48 3.46 
  
C6 26 21.4 55 4.02 
  
C7 26 23.7 50 3.29 
  
C8 30 25.4 51 4.22 
  
C9 25 21.8 45 4.28 
  
C10 26 20.4 49 4.22 
  
T1D 
T1 29 22.8 57 5.44 5 54 
T2 24 25.9 48 5.75 11 42 
T3 19 22.5 64 5.01 12 49 
T4 34 22.4 50 3.90 5 60 
T5 21 22.5 56 8.43 12 55 
T6 33 27.1 52 7.32 19 58 
T7 29 26.9 41 6.45 5 58 
T8 25 22.8 51 6.31 24 43 
T9 24 22.4 45 3.45 13 50 
T10 31 22.5 46 3.22 19 61 
VO2peak: peak oxygen uptake; BMI: Body mass index. Between group comparisons assessed 
with independent samples t-test. 
 
17 
Table 2 – OTUs which differ significantly between T1D and matched controls 
Group P value OTU Phylum Class Order Family Genus 
CON 0.003 Otu00082 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
CON 0.017 Otu01214 Firmicutes Bacilli Bacillales Bacillaceae_1 Anoxybacillus 
CON 0.019 Otu00865 Proteobacteria Alphaproteobacteria Rhizobiales Aurantimonadaceae Aurantimonas 
CON 0.021 Otu00820 Deinococcus-Thermus Deinococci Deinococcales Deinococcaceae Deinococcus 
CON 0.026 Otu00625 Firmicutes Clostridia Clostridiales Clostridiaceae_1 Clostridium_sensu_stricto 
CON 0.027 Otu00217 Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus 
CON 0.027 Otu00230 Proteobacteria Betaproteobacteria Burkholderiales unclassified unclassified 
CON 0.032 Otu00807 Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae Schlegelella 
CON 0.033 Otu01323 Proteobacteria Betaproteobacteria Burkholderiales unclassified unclassified 
CON 0.036 Otu01060 Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae unclassified 
CON 0.039 Otu00363 Proteobacteria Betaproteobacteria Rhodocyclales Rhodocyclaceae Zoogloea 
CON 0.041 Otu00384 Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae unclassified 
T1D 0.008 Otu00428 Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 
T1D 0.03 Otu00020 Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae Collinsella 
T1D 0.03 Otu00021 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
T1D 0.047 Otu00023 Firmicutes Clostridia Clostridiales Lachnospiraceae unclassified 
T1D 0.047 Otu00025 Firmicutes Negativicutes Selenomonadales Veillonellaceae Dialister 
18 
Figure Legends 
 
Figure 1 – Bar Chart of OTUs from type 1 (T1) diabetes and matched controls. Each 
OTU represented as a % of the total community. Samples ordered by Faecalibacterium 
abundance. 
Figure 2 – SIMCA analysis of type 1 (T1) diabetes samples and matched control. A) 
PCA score scatter plot. R2X[1] = 0.124, R2X[2] = 0.0998. B) Loadings Plot showing taxa 
associated with each group. Green (Y) represents each OTU detected, where only the 
significantly different OTUs between cases and control are labelled. Blue (X) shows different 
classification of the model, where OTUs associated with control samples are shown on the 
upper right and OTUs associated with cases are shown on the lower left. 
Figure 3 – Bar Chart of PICRUSt analysis from type 1 diabetes and matched controls. 
Each function represented as a % of the total community. Samples ordered in accordance 
with Figure 1. 
 
Supplementary Figure Legends 
Supplementary Figure 1 – PCA analysis of type 1 diabetes (T) samples and matched 
controls (C), with the T1D group split to account for differing glycaemic control.  T1D 
samples split by HbA1c >53 mmol/mol (orange) and HbA1c <53 mmol/mol with PLS-DA 
scores of -0.106 and 0.022, respectively. 
 
